FMO5 and Parkinson disease: Simvastatin reduced intracellular ROS levels, inhibited the activation of the NADPH oxidase/p38 mitogen-activated protein kinase (MAPK) pathway, and decreased NF-kappaB nuclear transcription in a mouse Parkinson’s disease model [24].